Australia's most trusted
source of pharma news
Thursday, 12 February 2026
Posted 12 February 2026 AM
In what's shaping up to be a David and Goliath battle, Perth-based Lawley Pharmaceuticals is challenging a failure by the PBAC to recommend a PBS listing for one of its drugs.
Lawley lodged an application in the Federal Court of Australia in January seeking judicial review of a decision by the PBAC at its November meeting in which it rejected AndroFeme 1, a topical treatment for post-menopausal women, for reimbursement.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.